Form 4: Biodesix CEO Scott Hutton Acquires Stock Options Through Bonus Program

Biodesix CEO Scott Hutton acquired 180,926 stock options on February 21, 2024, as part of the company's 2023 Bonus-to-Options Program.

Summary

• On February 21, 2024, Scott Hutton, the President and CEO of Biodesix Inc., acquired 180,926 stock options.
• The exercise price of these options is $1.46.
• The options vested fully on the grant date, February 21, 2024, and expire on February 20, 2034.
• These options were granted under Biodesix's 2023 Bonus-to-Options Program, where Hutton elected to receive a portion of his annual cash bonus in the form of fully-vested options.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The immediate vesting is a positive.

Positives

• The CEO's decision to take a portion of his bonus in stock options aligns his interests with those of the shareholders.
• The immediate vesting of the options provides an immediate incentive for the CEO.

Management Comments

• Under the Issuer's 2023 Bonus-to-Options Program, the Reporting Person elected to receive a portion of the annual cash bonus earned during 2023 in the form of a fully-vested option.

Industry Context

This type of equity compensation is common in the biotech industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Granting stock options as part of executive compensation is a standard practice among publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• Companies like Exact Sciences and Guardant Health also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the CEO's acceptance of stock options as a positive sign, aligning his interests with the company's long-term success.

Key Dates